Literature DB >> 24725667

Personalized medicine: present and future of breast cancer management.

Renaud Sabatier1, Anthony Gonçalves2, François Bertucci2.   

Abstract

Breast cancer is the first cause of cancer in women worldwide. Recent molecular analyses have shown that it is not a single disease but a mixture of several diseases with different biological behaviors, which should lead to treatment customization for each patient. Personalized medicine is based on tumor and/or patient molecular profiles. This new way to think oncology is currently applied at different stages of breast cancer management, including prognosis, prediction of treatment efficacy, and development of new therapies via new kinds of clinical trials. These trials are not only based on tumor site but also on tumor genetic characterization using genomic tools such as gene expression profiling, array-CGH or next-generation sequencing technologies. The aim of personalized medicine is to tailor treatment according to the specificities of a single disease in a given patient. In this review, we present the advances in treatment personalization which are currently used in daily practice as well as the technologies and therapies under investigation in various clinical trials.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Molecular profiling; Personalized medicine

Mesh:

Substances:

Year:  2014        PMID: 24725667     DOI: 10.1016/j.critrevonc.2014.03.002

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  18 in total

1.  Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?

Authors:  Christopher J Donnelly; Jonathan C Grima; Rita Sattler
Journal:  Neurodegener Dis Manag       Date:  2014

2.  Discovery of New Acid Ceramidase-Targeted Acyclic 5-Alkynyl and 5-Heteroaryl Uracil Nucleosides.

Authors:  Andrijana Meščić; Anja Harej; Marko Klobučar; Danijel Glavač; Mario Cetina; Sandra Kraljević Pavelić; Silvana Raić-Malić
Journal:  ACS Med Chem Lett       Date:  2015-10-05       Impact factor: 4.345

Review 3.  Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.

Authors:  Qi Yang; Christina L Parker; Justin D McCallen; Samuel K Lai
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

4.  Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.

Authors:  Michelle L Baglia; Qiuyin Cai; Ying Zheng; Jie Wu; Yinghao Su; Fei Ye; Ping-Ping Bao; Hui Cai; Zhiguo Zhao; Justin Balko; Wei Zheng; Wei Lu; Xiao-Ou Shu
Journal:  Breast Cancer Res Treat       Date:  2014-10-04       Impact factor: 4.872

5.  Somatic microsatellite variability as a predictive marker for colorectal cancer and liver cancer progression.

Authors:  Zalman Vaksman; Harold R Garner
Journal:  Oncotarget       Date:  2015-03-20

6.  An integrative transcriptomics approach identifies miR-503 as a candidate master regulator of the estrogen response in MCF-7 breast cancer cells.

Authors:  Jeanette Baran-Gale; Jeremy E Purvis; Praveen Sethupathy
Journal:  RNA       Date:  2016-08-18       Impact factor: 4.942

Review 7.  Balancing standardized testing with personalized training in surgery.

Authors:  Aadil Ahmed; Muhammad Abbas Abid; Nasir I Bhatti
Journal:  Adv Med Educ Pract       Date:  2016-12-28

8.  Mammalian sterile 20-like kinase 1 expression and its prognostic significance in patients with breast cancer.

Authors:  Xiao-Yan Lin; Feng-Feng Cai; Ming-Hong Wang; Xin Pan; Fang Wang; Lu Cai; Rong-Rong Cui; Su Chen; Ewelina Biskup
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

9.  Starvation stress attenuates the miRNA-target interaction in suppressing breast cancer cell proliferation.

Authors:  Jinhui Lü; Chuyi Zhang; Junyi Han; Zhen Xu; Yuan Li; Lixiao Zhen; Qian Zhao; Yuefan Guo; Zhaohui Wang; Evelyne Bischof; Zuoren Yu
Journal:  BMC Cancer       Date:  2020-07-06       Impact factor: 4.430

Review 10.  Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine?

Authors:  Lorenzo F Sempere
Journal:  Expert Rev Mol Diagn       Date:  2014-08-04       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.